

HR+/ HER2-VE Breast Cancer - Pipeline Insight, 2021

<https://marketpublishers.com/r/HE2759FAA4C9EN.html>

Date: July 2021

Pages: 90

Price: US\$ 2,500.00 (Single User License)

ID: HE2759FAA4C9EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "HR+/ HER2-VE Breast Cancer - Pipeline Insight, 2021," report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in HR+/ HER2-VE Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

HR+/ HER2-VE Breast Cancer Understanding

HR+/ HER2-VE Breast Cancer: Overview

HR+ breast cancers are those that express estrogen receptors (ER) or progesterone receptors (PR) or both. These tumors account for 70–80% of all breast cancers. These hormone-dependent cancers can often be treated successfully with a variety of drugs that modulate ER or reduce estrogen.

HER2 is short for human epidermal growth factor receptor. HER2 is sometimes called ERBB2, which stands for Erb-B2 receptor tyrosine kinase. HER2 is a gene that produces HER2 proteins, or receptors. If breast cancer cells don't have abnormal levels of HER2 proteins, the breast cancer is considered HER2-negative.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence HR+/ HER2-VE Breast Cancer R&D. The therapies under development are focused on novel approaches for HR+/ HER2-VE Breast Cancer.

HR+/ HER2-VE Breast Cancer Emerging Drugs Chapters

This segment of the HR+/ HER2-VE Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

HR+/ HER2-VE Breast Cancer Emerging Drugs

AZD9833: Astrazeneca

AZD-9833 acts as selective estrogen receptor degraders. It is being developed as combination therapy with palbociclib (a CDK4/6 inhibitor). It is currently in Phase III stage of development and is being developed by Astrazeneca.

BGB-290: BeiGene

Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated for the treatment of HER2 Negative Breast Cancer. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene's investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies. It is currently in Phase II stage of development for HER2-Negative Breast Cancer and is being developed by Beigene.

Further product details are provided in the report.....

HR+/ HER2-VE Breast Cancer: Therapeutic Assessment

This segment of the report provides insights about the different HR+/ HER2-VE Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on HR+/ HER2-VE Breast Cancer

There are approx. 40+ key companies which are developing the HR+/ HER2-VE Breast Cancer. The companies which have their HR+/ HER2-VE Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca.

Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

HR+/ HER2-VE Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

HR+/ HER2-VE Breast Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I,

preclinical and discovery stage. It also analyses HR+/ HER2-VE Breast Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HR+/ HER2-VE Breast Cancer drugs.

HR+/ HER2-VE Breast Cancer Report Insights

HR+/ HER2-VE Breast Cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

HR+/ HER2-VE Breast Cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing HR+/ HER2-VE Breast Cancer drugs?

How many HR+/ HER2-VE Breast Cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for HR+/ HER2-VE Breast Cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the HR+/ HER2-VE Breast Cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for HR+/ HER2-VE Breast Cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

BeiGene

H3 Biomedicine

AstraZeneca

Olema Pharmaceuticals

CytomX Therapeutics

Roche

G1 Therapeutics

Sanofi

Jiangsu HengRui Medicine

Key Products

BGB-290

H3B-6545

AZD9833

OP-1250

CX-2009

RG6171

Rintodestrant

Amcenestrant

SHR6390

Contents

- Introduction
- Executive Summary
- HR+/ HER2-VE Breast Cancer: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
 - Comparative Analysis
- AZD9833: Astrazeneca
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- BGB-290: BeiGene
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I/II)
 - Comparative Analysis
- OP-1250: Olema Pharmaceuticals
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Preclinical Stage Products
 - Comparative Analysis

Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....

Inactive Products
Comparative Analysis
HR+/ HER2-VE Breast Cancer Key Companies
HR+/ HER2-VE Breast Cancer Key Products
HR+/ HER2-VE Breast Cancer- Unmet Needs
HR+/ HER2-VE Breast Cancer- Market Drivers and Barriers
HR+/ HER2-VE Breast Cancer- Future Perspectives and Conclusion
HR+/ HER2-VE Breast Cancer Analyst Views
HR+/ HER2-VE Breast Cancer Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for HR+/ HER2-VE Breast Cancer

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for HR+/ HER2-VE Breast Cancer

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: HR+/ HER2-VE Breast Cancer - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/HE2759FAA4C9EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HE2759FAA4C9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970